Sarclisa Recommended for EU Approval by CHMP
Sarclisa's potential in treating newly diagnosed multiple myeloma gains traction.
Significant Study Findings
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently issued a favorable opinion recommending the approval of Sarclisa in combination with VRd therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). This recommendation is primarily based on noteworthy results from the GMMG-HD7 phase 3 study, where Sarclisa combined with bortezomib, lenalidomide, and dexamethasone demonstrated a remarkable increase in minimal residual disease (MRD) negativity rates and prolonged progression-free survival (PFS) when compared to the standard VRd regimen alone.
A Transformative Treatment Opportunity
If approved, this treatment could represent a significant advancement in multiple myeloma therapy, marking Sarclisa as the fourth approved indication in the EU and the second in a front-line setting globally. This is a huge step for patients eligible for autologous stem cell transplants and signifies the growing importance of innovative therapies in the management of multiple myeloma, ultimately aiming to enhance patient outcomes across the spectrum of the disease.
Insights from Sanofi Leadership
Olivier Nataf
Global Head, Oncology
“The CHMP’s recommendation signifies considerable progress in our quest for the widespread adoption of Sarclisa, addressing critical gaps in patient care for multiple myeloma. If approved, this treatment would provide a valuable new option for those facing this challenging disease, improving long-term treatment outcomes at essential points in the patient journey.”
Supporting Evidence and Clinical Trials
The positive opinion from the CHMP is grounded in the success of the two-part GMMG-HD7 study. The study has been pivotal in showcasing how Sarclisa can achieve deeper and quicker responses than traditional methods, especially in transplant-eligible patients with NDMM. It highlights the significant benefits of MRD negativity—which is an essential predictor of treatment effectiveness—showing that patients receiving Sarclisa with VRd could significantly enhance their treatment experience and outcomes.
Current Approvals and Future Potential
Sarclisa is already recognized in multiple indications throughout the EU for patients struggling with relapsed and/or refractory multiple myeloma. It is crucial to expand its reach to address the needs of a broader patient population. The evidence emerging from clinical trials underlines Sarclisa's role as a leading therapy in various settings.
About the GMMG-HD7 Study
The GMMG-HD7 study is an extensive, randomized trial involving numerous centers to evaluate the efficacy of Sarclisa alongside standard VRd treatment protocols in transplant-eligible patients. With a sizable participant group of 662 individuals, this study aims to redefine treatment strategies in myeloma care. Participants received therapies in cycles designed to maximize outcomes while minimizing risks.
Looking Forward: Sanofi's Commitment to Oncology
At Sanofi, the relentless drive to improve cancer treatment options remains at the forefront. The company is dedicated to advancing science and delivering innovative therapies for challenging cancers where significant need exists. The potential approval of Sarclisa represents not just a regulatory milestone but a beacon of hope for many individuals affected by multiple myeloma.
Contact Information for Media Inquiries
Media Relations
For further inquiries, reach out to:
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Frequently Asked Questions
What is Sarclisa used for?
Sarclisa is primarily used in the treatment of patients with multiple myeloma, both in relapsed/refractory and newly diagnosed stages, particularly for those eligible for transplants.
What did the GMMG-HD7 study find?
The GMMG-HD7 study discovered that Sarclisa combined with VRd treatment significantly increased MRD negativity rates and prolonged PFS compared to VRd alone.
What would the approval mean for Sarclisa?
An approval would enhance Sarclisa's accessibility as a treatment option, benefiting patients with multiple myeloma and expanding its indications within the EU.
How is Sanofi involved in myeloma treatment advancements?
Sanofi is actively involved in research and development to innovate therapies for multiple myeloma, focusing on improving treatment outcomes and patient care globally.
Where can I find more information about Sarclisa?
For additional details and clinical study information, please visit clinical trial registries or Sanofi’s official website.
